Category Archives: Pathogenesis

Fever!

Most viral infections start out with the same general symptoms: fever, malaise, aches. Those are usually the sign of your immune system starting to fight back. Fever is one of our defense mechanisms, and while it can be quite uncomfortable it is very rarely dangerous. One of the common questions I get asked in my classes is whether it is good or bad to take fever reducing medicines when you are sick. Well, Im not that kind of doctor so I can’t really answer that question, but I can tell you what research has been done on the benefits of fever.

The adaptive value of Saturday Night Fever, caused by listening to Disco, remains unknown

Presumably, by raising your body temperature, you can do a better job of fighting off an infection. The higher temperature may make it more difficult for the pathogen to grow because it grows optimally only at normal body temperature, or it may help the immune system work faster (or both). Some studies in animals have shown that reducing fever results in increased growth of bacteria or virus in the infected animal, and other studies have found increased proliferation, migration and activity of immune cells.

Whatever the mechanism, it is clear that fever must provide some advantage. There are many studies that demonstrate that fever is beneficial in overcoming infection. None of these studies alone is definitive, however taken together, they do seem to support a role for fever in fighting infection. For one, the febrile response is highly conserved in vertebrates (even “cold blooded” animals) and many invertebrates. Some lizards, for example, will seek warmer spots to rest and as a result, raise their body temperature when infected. Fever is also energetically very expensive, requiring 20% more energy to maintain a temperature even a few degrees above normal. It would be unlikely for such an expensive mechanism to be maintained by natural selection if it didn’t have some benefit.

In addition to the evolutionary perspective, several studies in animals show that a fever of a few degrees correlates with better survival rate from infection. Being correlations, we must be cautious in over-interpreting this. Another good way to test if something like fever is useful is to get rid of it. Infected animals can be treated with anti-pyretic (fever reducing) drugs to see what happens to their recovery in the absence of fever. These studies typically show that animals treated with anti-pyretic drugs take longer to recover, and in some cases even to increased mortality. There are some problems with anti-pyretic studies however, and one of the major problems is that many anti-pyretic drugs don’t just reduce fevers. They can have other effects on the body, not all of which are known, and so we can’t always be certain that fever reduction is the reason for the changes in morbidity and mortality.

Of course, I also like to look at the pathogens themselves for hints of what our immune system is doing. They are pretty good at defending themselves against our immune response, so if we look at their defenses we can learn more about how we attack them. The poxvirus Vaccinia encodes a protein that blocks fever. This protein interferes with the function of interleukin-1B, a component of our own immune system that regulates fever. Animals infected with Vaccinia lacking that protein develop fever, showing that when the viral protein is present, the virus can prevent fever. However, interleukin-1B does many other things too, not just regulation of fever, so it is possible that the virus is blocking interleukin-1B for a different reason.

So it is highly likely that fever is good for fighting off infections, but this is not to be taken as medical advice to avoid fever reducing medicines. In the case of naturally occurring infections in humans, we need much more research into fevers resulting from specific infections to decide when a fever is beneficial and should be left alone, whether the fever is dangerous, or if the fever is helpful but the risks of taking an anti-pyretic are worth alleviating the uncomfortable symptoms.

References:
Kluger, M.J. (1996) The adaptive value of fever. Infectious disease clinics of north america. 1(10):1-20.
Alcami, A. and Smith, G.L. (1996) A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci. 93:11029-11034.

Share

H5N1 Ferret Transmission Experiment Published

At last, one of the papers investigating H5N1 influenza transmission in ferrets has been published in the journal Nature yesterday.  To recap the controversy briefly:  news of experimental studies investigating transmissibility of avian H5N1 influenza hit the news this fall, igniting a fierce debate about biosecurity, “dual use” research, and the damage that censorship can have on scientific advancement.  An advisory group, the NSABB, recommended partial censorship of the data, perhaps believing that redacting specific data from the publications would prevent information on how to generate a highly pathogenic mammalian transmissible virus from getting into the hands of bioterrorists or others incapable of handling such viruses safely.  However, after some new data or clarification of data presented in a revised version of the submitted manuscript, the NSABB recommended publication in full.

Avian H5N1 influenza virus has caused sporadic infections in humans who have close contact with infected animals.  Human-to-human transmission has not been observed.  But could an H5 virus mutate or reassort, allowing human-to-human transmission?

One thing that has been lost in this whole controversy is that this study is actually a great demonstration and application of evolution.  How does a virus switch to a new host and transmit efficiently between individuals?  Start with a diverse population that varies in a particular trait (in this case, ability to bind the human receptor).  Put it through selective pressure. This occurred in several steps: first, select for viruses that can bind the human receptor in vitro.  From those that bind, select ones that can efficiently replicate in the respiratory tract of the animal.  Finally, take the efficient replicators and allow for transmission.  At each step of selection, mutations that naturally occur during viral replication further diversify the population resulting in variants that possess the desired property.  Those variants get selected for the next experiment.

This study focused on one particular influenza virus protein, hemagglutinin (HA).  HA is on the surface of the virion and is what the virus uses to attach to the host cell, the first step in viral infection.  HA of human influenza viruses bind a sugar on the surface of human cells, which is slightly different from that found in the avian respiratory tract.  Avian viruses, of course, bind to the form found in birds.  H5 shows a strong preference for binding the avian receptor, so Karaoka et al were interested in finding out if H5 could change to recognize the human receptor, allowing more efficient transmission between mammals.

To address this, they began with a mutagenesis technique to introduce random mutations in the globular head (the receptor binding part) of HA, then used an in vitro approach to select for mutants that bound the human receptor (selection step 1).  Through this process they identified three H5 variants that gained the ability to bind the human receptor while maintaining the ability to bind the avian receptor, and one that switched specificity completely to the human receptor.  Several of the mutations identified in this study had already been shown in previous studies to be important in receptor specificity.

To test if the variant H5s conferred binding to human receptors in vivo, sections of human tracheal tissue were exposed to the viruses and only two were able to infect (selection step 2).  This suggests the virus can infect human epithelium of the upper respiratory tract.

Next, the two remaining variants were used to infect ferrets.  Both replicated in ferret respiratory tracts, but one replicated to higher levels.  When they sequenced the virus that they isolated from that ferret, it was different from what they had put in: a new mutation had appeared.  This new mutation presumably confers the property of better replication in the ferret respiratory tract, so it outgrew the original input virus (selection step 3).

Using this new virus (now with a total of 3 mutations in H5), transmission was tested in ferrets.  Compared to the original H5, which did not transmit via aerosol, the 3-mutation variant did transmit, although between only 2 of 6 animal pairs.  Again, they sequenced the virus that was present in the contact animals and found that it was different than what had gone in to the inoculated animals.  Yet another mutation had appeared (selection step 4).  This additional mutation appears to enhance transmission:  the new virus, now with 4 mutations, transmitted more quickly and between more pairs of animals than the 3-mutation virus.  Although the virus can transmit, none of the infected animals died, but they did show pathology at the site of infection.

So what does this all mean? The best model available for influenza transmission studies is ferrets.  Ferrets aren’t humans, so its important to keep in mind that this is a model that helps us understand what viral or host factors are involved in aerosol transmission in these mammals, and maybe, but not necessarily, in humans.  Since we don’t know what is necessary for human-to-human transmission, it is valuable to have an animal model to give us some ideas of what to look for.  It can provide some good hypotheses on what mediates transmission in humans, which would then have to be further tested.  Obviously, specificity for the human receptor is necessary, but the mutations identified tell us more than that.  Mutations that change specificity are not sufficient for transmission.  It turns out that those mutations also decrease the stability of the HA protein.  The additional mutations acquired through the selection steps compensate for that, and enhance stability.   So now we know that HA stability is important in influenza transmission.  Between ferrets.  That’s probably true for humans too, but it would need to be tested.

If you are still reading, you are obviously procrastinating, and are probably avoiding studying for your final exam.  But here are some more thoughts on the controversy overall.  This is a really interesting paper, with nothing particularly frightening or worrisome about it.  Certainly not any more so than other papers doing similar work that were published without so much controversy.  If “dual use” research needs to be regulated, it needs to be done before the work is done, not after.  If the NSABB was concerned about this kind of research, why only express concern once the experiment succeeds?  In my intro biology class, we read another paper, published in 2005, which was addressing the exact same question, in an almost identical way.  The difference is that they failed to make a transmissible virus.  If there is a concern about this kind of research, a concern that it is too risky to do these kinds of experiments, shouldn’t the alarm have been raised regardless of the outcome?  It just doesn’t make sense to me why it suddenly became so concerning.  If anything good has come of this controversy, it is the widespread discussion that this has stimulated on the importance of open communication of scientific data, the importance of not censoring in science.  Ironically, had we all been given access to the data, like through a journal publication, it would have been apparent that there wasn’t anything to be concerned about.

Share

Mouse Pneumonia: Are We to Blame?

Contributed by guest blogger: Alix Zongrone ’12

Pneumonia virus of mice, or PVM, is the leading cause of pneumonia in laboratory mice; however, lack of evidence of PVM in wild rodents has left scientists in the dark with regards to the history and natural host of the virus. Because PVM is mostly found in captive settings (i.e. laboratories, pet shops, etc.) and PVM-neutralizing behavior has been observed in human cells, it has been suggested that human contact may play a pivotal role in the virus’s spread. Several studies have sought to investigate the prevalence of PVM in humans and its role in human respiratory infection; however, since PVM is closely related to human respiratory syncytial virus, or RSV, it is difficult to make sound conclusions based on this evidence alone.

Due to the evidence of PVM in humans, researchers inoculated two different non-human primate species with PVM to investigate replication activity of PVM in these mammals. They found that, over the course of twelve days, most of the samples exhibited viral replication as well as viral shedding. Although not all of the animals showed virus replication and shedding behavior, PVM antibodies were found in all test animals, suggesting that infection did take place, but replication was highly restricted. Though PVM was observed to not replicate well in non-human primates, human lung epithelial cells exhibited similar permissiveness of both PVM and RSV in vitro.
Controlling the interferon (IFN) immune response is a known mechanism of successful viral replication in the host. Researchers investigated the ability of PVM to block IFN response to further explore PVM host range restriction. The virus demonstrated an ability to block IFN response in these human epithelial cells thanks to the NS2 protein. However, a Western blot was used to compare proteins made from PVM and RSV and  PVM-neutralizing activity specificity was also determined. Humans were tested for PVM antibodies to examine whether an immune response was triggered. No PVM antibodies were found in the human sera, and no reactivity between PVM proteins and observed PVM-neutralizing behavior was recorded. This demonstrates a lack of immune response in the human cells.
Although PVM was observed to replicate in vitro in human epithelial cells, the results remain inconclusive as to whether or not the virus should be considered a human pathogen. The lack of permissiveness in non-human primates suggests that the virus may not actually cause infection in humans. This is supported by the lack of reaction shown between PVM proteins and PVM-neutralizing activity in the Western Blot.
Questions remain as to the nature of the PVM-neutralizing activity in human serum as well the origin of PVM and its natural host. Is that which is categorized as PVM-neutralizing behavior not actually PVM-specific? What is causing PVM in captive laboratory mice but not in wild rodent species?  Finally, what could possibly be the natural host of pneumonia virus of mice, if not mice?

Link: http://jvi.asm.org/content/86/10/5829.abstract?etoc

Alix Zongrone is a senior at Vassar College, majoring in biology.

Share